ZA201605492B - Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same - Google Patents

Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Info

Publication number
ZA201605492B
ZA201605492B ZA2016/05492A ZA201605492A ZA201605492B ZA 201605492 B ZA201605492 B ZA 201605492B ZA 2016/05492 A ZA2016/05492 A ZA 2016/05492A ZA 201605492 A ZA201605492 A ZA 201605492A ZA 201605492 B ZA201605492 B ZA 201605492B
Authority
ZA
South Africa
Prior art keywords
hepe
methods
same
pharmaceutical compositions
treating asthma
Prior art date
Application number
ZA2016/05492A
Other languages
English (en)
Inventor
Duffy Kevin
Climax John
Manku Mehar
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of ZA201605492B publication Critical patent/ZA201605492B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/327Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2016/05492A 2014-01-10 2016-08-08 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same ZA201605492B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461926052P 2014-01-10 2014-01-10
PCT/US2015/011054 WO2015106215A2 (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Publications (1)

Publication Number Publication Date
ZA201605492B true ZA201605492B (en) 2018-11-28

Family

ID=53520398

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/05492A ZA201605492B (en) 2014-01-10 2016-08-08 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Country Status (15)

Country Link
US (2) US20150196521A1 (OSRAM)
EP (1) EP3091959A4 (OSRAM)
JP (2) JP2017505809A (OSRAM)
KR (1) KR20160132372A (OSRAM)
CN (1) CN106029051A (OSRAM)
AU (1) AU2015204531B2 (OSRAM)
BR (1) BR112016015997A2 (OSRAM)
CA (1) CA2935986A1 (OSRAM)
IL (1) IL246623A0 (OSRAM)
MX (1) MX2016008953A (OSRAM)
PH (1) PH12016501371A1 (OSRAM)
RU (2) RU2685706C2 (OSRAM)
SG (2) SG10202000496XA (OSRAM)
WO (1) WO2015106215A2 (OSRAM)
ZA (1) ZA201605492B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
HK1247136A1 (zh) * 2015-01-16 2018-09-21 Afimmune Limited 包含15-hepe的组合物和其使用方法
EP3861995A1 (en) * 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
ATE344226T1 (de) * 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20060160095A1 (en) * 2002-12-13 2006-07-20 Eirx Therapeutics Limited Survivin
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
HRP20160373T1 (hr) * 2005-03-16 2016-05-06 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ3系脂肪酸由来の新規抗炎症性代謝物
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Also Published As

Publication number Publication date
CA2935986A1 (en) 2015-07-16
IL246623A0 (en) 2016-08-31
KR20160132372A (ko) 2016-11-18
RU2019110980A (ru) 2019-08-26
BR112016015997A2 (pt) 2018-03-27
RU2685706C2 (ru) 2019-04-23
PH12016501371A1 (en) 2016-08-15
WO2015106215A3 (en) 2016-02-18
EP3091959A4 (en) 2017-09-20
JP2020002150A (ja) 2020-01-09
SG10202000496XA (en) 2020-03-30
WO2015106215A2 (en) 2015-07-16
RU2016132762A (ru) 2018-02-16
US20150196521A1 (en) 2015-07-16
AU2015204531B2 (en) 2019-11-14
US20160324820A1 (en) 2016-11-10
SG11201605601UA (en) 2016-08-30
RU2016132762A3 (OSRAM) 2018-09-20
JP2017505809A (ja) 2017-02-23
CN106029051A (zh) 2016-10-12
AU2015204531A1 (en) 2016-08-18
EP3091959A2 (en) 2016-11-16
MX2016008953A (es) 2017-02-02

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL251066A0 (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL265881A (en) Inhaler and methods of use thereof
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL255565A (en) Substituted benzamides and methods of use thereof
GB201410250D0 (en) Improvements to nasal compositions and method of use thereof
IL320533A (en) Methods and compositions for treating disorders and diseases involving RDH12
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
EP3154616A4 (en) Methods and apparatus for treatment of respiratory disorders
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
GB201408387D0 (en) Treatment of respiratory disorders
ZA201802134B (en) Therapeutic compounds and methods of use thereof
PT3233233T (pt) Composições despumantes compreendendo partículas anfifílicas e métodos de preparação e utilização das mesmas
GB201511799D0 (en) Composition and methods of treatment
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
EP3151862A4 (en) Therapeutic detoxification compositions and methods of making and using same
EP3280406A4 (en) COMPOSITIONS AND METHODS FOR TREATING MOVEMENT DISORDERS
ZA201805989B (en) Compositions and methods of treatment of chronic infectious diseases